On January 13, 2026, Pacira BioSciences, the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL^® (bupivacaine liposome injectable suspension), Pacira’s long-acting, local analgesic for postsurgical pain management in the region. Wilson Sonsini Goodrich & Rosati advised Pacira on the transaction.

The Wilson Sonsini team that advised Pacira on the transaction was led by Seth Flaum and Aleks Vitomirov.

For more information, please see Pacira’s news release.